Patent classifications
A61K35/32
PRODUCTION METHOD FOR SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS AND PRODUCTION METHOD FOR CELL PREPARATION FOR JOINT MEDICAL TREATMENT
An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, by which proliferation efficiency is improved so that a sufficient amount of synovium-derived mesenchymal stem cells can be obtained from a synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which is a method of producing a synovium-derived mesenchymal stem cell from a synovial tissue, where the production method includes treating the synovial tissue with a mixed enzyme including one or more kinds of collagenases and one or more kinds of neutral proteases for 2 hours or more without causing the synovial tissue to undergo a disinfection step.
PRODUCTION METHOD FOR SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS AND PRODUCTION METHOD FOR CELL PREPARATION FOR JOINT MEDICAL TREATMENT
An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.
Tissue-engineered intervertebral disc with living cells
The present invention relates to a tissue-engineered intervertebral disc (IVD) comprising a nucleus pulposus structure comprising a first population of living cells and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and collagen.
Tissue-engineered intervertebral disc with living cells
The present invention relates to a tissue-engineered intervertebral disc (IVD) comprising a nucleus pulposus structure comprising a first population of living cells and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and collagen.
IgG type monoclonal antibodies specifically binding to odontoblast surface
The present invention relates to a composition for the differentiation of dental pulp stem cells into odontoblasts and an IgG or IgM type monoclonal antibody that specifically binds to the surface of odontoblasts differentiated from the stem cells. According to the present invention, BMP2 and BMP4 are optimally combined to significantly increase the differentiation efficiency of dental pulp stem cells into odontoblasts, to induce the mineralization of the matrix, and to improve the differentiation ability of odontoblasts into dentin. Further, the IgG or IgM monoclonal antibody that specifically binds to the surface of odontoblasts of the present invention is used to effectively isolate and purify odontoblasts, which can be useful for tissue regeneration and differentiation.
IgG type monoclonal antibodies specifically binding to odontoblast surface
The present invention relates to a composition for the differentiation of dental pulp stem cells into odontoblasts and an IgG or IgM type monoclonal antibody that specifically binds to the surface of odontoblasts differentiated from the stem cells. According to the present invention, BMP2 and BMP4 are optimally combined to significantly increase the differentiation efficiency of dental pulp stem cells into odontoblasts, to induce the mineralization of the matrix, and to improve the differentiation ability of odontoblasts into dentin. Further, the IgG or IgM monoclonal antibody that specifically binds to the surface of odontoblasts of the present invention is used to effectively isolate and purify odontoblasts, which can be useful for tissue regeneration and differentiation.
Cartilage material having minimal hypertrophy and robust integration capacity, and uses therefor
A method is provided for producing a live cartilaginous material useful for implantation into a patient. A method of treating a patient comprising implanting a cartilaginous material prepared according to the provided method in an anatomical site in a patient also is provided.
DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF
The present disclosure provides improved biomaterials extracted from fibrous meniscal cartilage (FMC). The materials are at least partially decellularized and enzyme treated to remove at least a portion of the elastin and blood vessels found in FMC. Such biomaterials can be employed as tissue scaffolds, such as in transplant procedures.
TISSUE PROCESSING APPARATUS AND METHOD FOR PROCESSING ADIPOSE TISSUE
Harvested adipose tissue is processed in a single-use portable processing container to prepare a centrifuges pellet phase of stromal vascular fraction concentrate, which is selectively removed and disposed in a syringe dispersed in a dispersion medium to prepare an osteoarthritis treatment product.
TISSUE PROCESSING APPARATUS AND METHOD FOR PROCESSING ADIPOSE TISSUE
Harvested adipose tissue is processed in a single-use portable processing container to prepare a centrifuges pellet phase of stromal vascular fraction concentrate, which is selectively removed and disposed in a syringe dispersed in a dispersion medium to prepare an osteoarthritis treatment product.